http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-008494-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4152 |
| filingDate | 1997-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2000-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-008494-A1 |
| titleOfInvention | USE OF PIRAZOLINONES FOR THE TREATMENT OF POWER DISORDERS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, USE OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND / OR THERAPY OF POWER DISORDERS AND A PROCEDURE FOR PREPARING |
| abstract | The invention relates to the use of the pyrazolinones of formula (I) in which R1 represents unsubstituted or monosubstituted benzyl or monosubstituted with alkoxy, ofenyl or pyridyl or mono, di or trisubstituted with Hal, NO2, CN, COOH, CONH2, CONHA, CONAA, NH2, NH-CO-A, NH-SO2A, NA-SO2A, NH-CO-OA, SO3H, SO2NH-CO-A, SO2NR4R5, CO-NHSO3H, CO-NHSO2A, tetrazolyl or PO3H. R2 represents A, alkoxy-CO-alkylene, HO-CO-alkylene or HO-alkylene, R3 represents H, A, alkoxy, NH2, NHA, NAA, NH-CO-A or SO2NR4R5; R4, R5 independently represent H or A Together R4 and R5 also represent a 4- to 5-membered fully or partially unsaturated saturated alkylene chain, in which 1 to 3 C atoms can be replaced by N and / or 1 to 2 C atoms can be replaced by 1 to 2 O atoms and / or 1 to 2 S atoms. A, A independently represent alkyl of 1 to 6 C atoms, wherein 1 to 7 H atoms may be replaced by F and / or Cl atoms. Hal represents F, Cl, Br or I, for the treatment and / or therapy of potency disorders. It also relates to pharmaceutical preparations containing such compounds, their use for the treatment and / or therapy of potency disorders, and a method of preparing them. The compounds of formula (I) and their physiologically acceptable salts can be used to combat diseases in which an increase in the level of cGMP (cyclic guanosine monophosphate) stops or prevents inflammation and relaxes the muscles. In particular, these compounds can be used for the treatment of diseases of the cardiovascular system and for the treatment and therapy of disorders of potency. |
| priorityDate | 1996-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.